Scilex Holding Co (SCLX)

↓ Download CSV

CIK 0001820190 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Scilex Holding Co reported revenue of $30.25M, down 46.5% from the prior year. The company ran a net loss, with a net margin of -1236.4% and a gross margin of 415.8%. It held $364.98M in total assets against $576.73M in total liabilities.

Key ratios (FY2025)

415.8%
Gross margin
-1143.7%
Operating margin
-1236.4%
Net margin
-46.5%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$30.25M$56.59M$46.74M$38.03M$31.32M$23.56M
Cost of Revenue$10.60M$16.69M$15.68M$10.80M$3.63M$2.15M
Gross Profit$125.80M$167.40M
Operating Income-$346.01M-$83.40M-$105.43M-$50.63M-$35.84M-$35.26M
Net Income-$374.05M-$72.81M-$114.33M-$23.36M-$88.42M-$47.52M
EPS (Diluted)$-36.48$-8.05$-1.28$-0.17$-0.67$-0.36
Total Assets$364.98M$92.95M$101.31M$86.53M$77.93M$199.5K
Total Liabilities$576.73M$285.59M$274.25M$50.29M$301.81M$180.8K
Shareholders' Equity-$211.75M-$192.64M-$172.94M$36.24M-$223.88M-$141.68M-$90.03M
Cash & Equivalents$4.96M$3.27M$3.92M$2.18M$4.34M$30.5K
Operating Cash Flow$3.82M$19.35M-$20.71M-$21.26M-$28.66M-$31.46M
Capital Expenditures$133.0K$0$30.0K$7.0K$0$25.0K
Shares Outstanding7.03M5.24M100.02M141.35M132.86M3.45M